Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025)

Cyclerion Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 40.3% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 2717.0% year-over-year to 40.3%; the TTM value through Sep 2025 reached 40.3%, up 2717.0%, while the annual FY2024 figure was 33.75%, 6119.0% up from the prior year.
  • Return on Capital Employed for Q3 2025 was 40.3% at Cyclerion Therapeutics, up from 42.63% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 40.11% in Q1 2025 and troughed at 354.88% in Q1 2023.
  • A 5-year average of 128.29% and a median of 105.23% in 2021 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: plummeted -22876bps in 2023 and later skyrocketed 25154bps in 2024.
  • Year by year, Return on Capital Employed stood at 105.23% in 2021, then plummeted by -141bps to 253.89% in 2022, then soared by 58bps to 106.08% in 2023, then skyrocketed by 60bps to 42.62% in 2024, then rose by 5bps to 40.3% in 2025.
  • Business Quant data shows Return on Capital Employed for CYCN at 40.3% in Q3 2025, 42.63% in Q2 2025, and 40.11% in Q1 2025.